1-5 of 5
Leif W. Ellisen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

James T. Coates, Sheng Sun, Ignaty Leshchiner, Nayana Thimmiah, Elizabeth E. Martin, Daniel McLoughlin, Brian P. Danysh, Kara Slowik, Raquel A. Jacobs, Kahn Rhrissorrakrai, Filippo Utro, Chaya Levovitz, Elyssa Denault, Charlotte S. Walmsley, Avinash Kambadakone, James R. Stone, Steven J. Isakoff, Laxmi Parida, Dejan Juric, Gad Getz, Aditya Bardia, Leif W. Ellisen
Journal: Cancer Discovery
Cancer Discov (2021) 11 (10): 2436–2445.
https://doi.org/10.1158/2159-8290.CD-21-0702
Published: 01 October 2021
View article titled, Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer
Open the PDF for Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer

Carlotta Costa, Ye Wang, Amy Ly, Yasuyuki Hosono, Ellen Murchie, Charlotte S. Walmsley, Tiffany Huynh, Christopher Healy, Rachel Peterson, Shogo Yanase, Charles T. Jakubik, Laura E. Henderson, Leah J. Damon, Daria Timonina, Ioannis Sanidas, Christopher J. Pinto, Mari Mino-Kenudson, James R. Stone, Nicholas J. Dyson, Leif W. Ellisen, Aditya Bardia, Hiromichi Ebi, Cyril H. Benes, Jeffrey A. Engelman, Dejan Juric
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (1): 72–85.
https://doi.org/10.1158/2159-8290.CD-18-0830
Published: 09 January 2020
View article titled, PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Open the PDF for PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor–Positive Breast Cancer

Karina J. Matissek, Maristela L. Onozato, Sheng Sun, Zongli Zheng, Andrew Schultz, Jesse Lee, Kristofer Patel, Piiha-Lotta Jerevall, Srinivas Vinod Saladi, Allison Macleay, Mehrad Tavallai, Tanja Badovinac-Crnjevic, Carlos Barrios, Nuran Beşe, Arlene Chan, Yanin Chavarri-Guerra, Marcio Debiasi, Elif Demirdögen, Ünal Egeli, Sahsuvar Gökgöz, Henry Gomez, Pedro Liedke, Ismet Tasdelen, Sahsine Tolunay, Gustavo Werutsky, Jessica St. Louis, Nora Horick, Dianne M. Finkelstein, Long Phi Le, Aditya Bardia, Paul E. Goss, Dennis C. Sgroi, A. John Iafrate, Leif W. Ellisen
Journal: Cancer Discovery
Cancer Discov (2018) 8 (3): 336–353.
https://doi.org/10.1158/2159-8290.CD-17-0535
Published: 01 March 2018
View article titled, Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor–Positive Breast Cancer
Open the PDF for Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma

Lei He, Kristine Torres-Lockhart, Nicole Forster, Saranya Ramakrishnan, Patricia Greninger, Mathew J. Garnett, Ultan McDermott, Stephen M. Rothenberg, Cyril H. Benes, Leif W. Ellisen
Journal: Cancer Discovery
Cancer Discov (2013) 3 (3): 324–337.
https://doi.org/10.1158/2159-8290.CD-12-0417
Published: 07 March 2013
View article titled, Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma
Open the PDF for Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Yasir H. Ibrahim, Celina García-García, Violeta Serra, Lei He, Kristine Torres-Lockhart, Aleix Prat, Pilar Anton, Patricia Cozar, Marta Guzmán, Judit Grueso, Olga Rodríguez, Maria Teresa Calvo, Claudia Aura, Orland Díez, Isabel T. Rubio, José Pérez, Jordi Rodón, Javier Cortés, Leif W. Ellisen, Maurizio Scaltriti, José Baselga
Journal: Cancer Discovery
Cancer Discov (2012) 2 (11): 1036–1047.
https://doi.org/10.1158/2159-8290.CD-11-0348
Published: 11 November 2012
View article titled, PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Open the PDF for PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition in another window
Includes: Supplementary data